CJC-1295 (with DAC): Research Roundup

CJC-1295 with DAC (Drug Affinity Complex) is a modified growth hormone releasing hormone (GHRH) analog engineered for extended activity through covalent binding to serum albumin. The peptide core derives from GHRH(1-29) with amino acid substitutions that reduce enzymatic degradation, while the DAC moiety — a reactive maleimidoproprionic acid linker — enables conjugation to albumin after administration in pharmacokinetic studies. This design targets sustained elevation of GH and IGF-1 in research models compared with unmodified or shorter-acting GHRH fragments. CJC-1295 with DAC is chemically and pharmacokinetically distinct from CJC-1295 without DAC, a tetrasubstituted GHRH(1-29) analog that lacks albumin binding. Confusing the two is one of the most common errors in GH-axis research material selection. This roundup covers published pharmacology, comparisons within the secretagogue class including ipamorelin and GHRP-2, and documentation requirements for research-grade lots.

What the literature describes

Teichman and colleagues reported the pharmacokinetics and pharmacodynamics of CJC-1295 with DAC in formal research settings, documenting extended GH and IGF-1 elevation following administration in study protocols designed to characterize duration of action. The albumin-binding strategy extends half-life by reducing renal clearance and proteolytic degradation — a well-established approach in peptide medicinal chemistry that distinguishes this form from native GHRH and from shorter-acting analogs.

In preclinical models, GHRH analogs stimulate GH release through pituitary GHRH receptors, mimicking the hypothalamic signal that triggers pulsatile GH secretion. The DAC-modified form alters the temporal profile of that stimulation: rather than brief pulses characteristic of endogenous GHRH release, pharmacokinetic studies report sustained GH elevation patterns. Whether sustained elevation faithfully models physiological GH dynamics or represents a pharmacological supraphysiological state is an active research question — one that affects how investigators interpret endpoints in animal studies.

Human phase 1 pharmacology literature exists for CJC-1295 with DAC under defined trial conditions. That work characterizes what was observed in those specific protocols — dose ranges, monitoring schedules, and measured endpoints — not general recommendations for research material use outside formal study frameworks. The compound did not proceed to approved therapeutic status, which catalog marketing sometimes obscures.

Research discussions frequently pair CJC-1295 with ghrelin mimetics. GHRH analogs and GHS-R agonists stimulate GH through complementary pituitary pathways; preclinical literature examines whether combined administration produces additive or synergistic GH elevation compared with either class alone. Ipamorelin, GHRP-6, GHRP-2, and hexarelin each bring distinct receptor pharmacology to such combinations. Published combination data remain predominantly animal-based, and material from current catalogs may differ from trial formulations in salt form, excipients, and impurity profiles.

DAC modification: chemical and analytical implications

The DAC group changes what mass spectrometry should show. Identity confirmation must account for the peptide-plus-linker expected mass, not the unmodified GHRH(1-29) sequence alone. Vendors who report MS data for the wrong molecular species — the no-DAC mass on a DAC-labeled product, or vice versa — fail the most basic identity check. HPLC purity on a DAC-modified peptide may show different retention behavior than the unmodified analog; chromatographic comparison across forms is not interchangeable.

Storage and handling characteristics may also differ. Albumin-binding peptides and their reactive linker precursors can degrade through hydrolysis, oxidation, or aggregation depending on formulation. A COA from synthesis date does not guarantee stability at receipt. Researchers should evaluate appearance, solubility behavior, and repeat identity checks when material has been stored for extended periods — principles covered in our peptide identity testing guide.

The naming landscape adds confusion. Catalogs use "CJC-1295," "CJC-1295 with DAC," "DAC-CJC," and variant spellings. CJC-1295 without DAC may appear as "mod GRF 1-29," "Modified GRF," or "CJC-1295 no DAC." Treat every label as unverified until MS confirms the expected structure.

Research design considerations

Experiments examining IGF-1 kinetics, body composition endpoints, or pituitary feedback loops must account for the sustained GH elevation profile that DAC modification produces. Models calibrated for pulsatile GH — the physiological pattern driven by hypothalamic GHRH and somatostatin interplay — may not accommodate prolonged GHRH analog exposure without reinterpretation of results. Review Teichman et al. and related pharmacokinetic sources for the specific temporal profiles reported rather than assuming equivalence with no-DAC literature.

When combining CJC-1295 with DAC alongside ghrelin mimetics, receptor-level complementarity does not guarantee additive effects at every dose or in every species. Ipamorelin spares certain off-target endpoints in comparative assays; GHRP-6 does not. Hexarelin brings high GHS-R potency and a separate cardiac research literature thread. Combination study design should specify which secretagogue class properties are relevant to the endpoint and verify each peptide independently before mixing.

Material handling deserves explicit protocol documentation. DAC-modified peptides may behave differently during reconstitution and storage than unmodified sequences. Document lot numbers, COA dates, and storage conditions in lab notebooks so results remain traceable if identity questions arise later.

Important limitations

• Not interchangeable with no-DAC. DAC and no-DAC forms differ in mass, PK profile, duration of GH elevation, and published pharmacology. They are separate research materials.
• Trial vs. catalog gap. Phase 1 literature used specific formulations under protocol. Research-grade catalog material may differ in composition and purity.
• Sustained GH elevation concerns. Pharmacokinetic studies report prolonged GH elevation patterns that may not reflect physiological pulsatility. Endpoint interpretation in research models requires caution.
• Combination protocols unvalidated. Pairing with ipamorelin or GHRP-class peptides reflects laboratory interest, not established standard protocols.
• No administration content. Dosing, routes, and reconstitution guidance are excluded from this page.

Evaluating the material

Demand per-batch documentation that confirms both sequence identity and DAC modification through mass spectrometry. HPLC should include a chromatogram with method description, not an isolated purity percentage. Lot numbers on the COA must match the vial label.

Start with COA literacy to evaluate completeness. Understand the complementary roles of chromatographic purity and mass confirmation in HPLC vs. MS. Compare analytical expectations against the no-DAC analog if your research requires the shorter-acting form instead.

Our vetting scorecards assess vendor transparency on exactly these points — independent lab attribution, batch-specific data, and consistency between product labels and analytical results.

Related secretagogue literature

CJC-1295 with DAC belongs to the GHRH analog branch of the GH secretagogue research tree, alongside CJC-1295 no DAC and complementary to ghrelin mimetics ipamorelin, GHRP-2, GHRP-6, and hexarelin. Each compound in this series has a dedicated roundup comparing published evidence and material quality expectations.

Questions about the research literature? Use the discussion below — research framing only, no human-use instructions.